News | Coronavirus (COVID-19) | March 16, 2020| Dave Fornell, Editor

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

The European Society of Cardiology (ESC) is recommending in novel coronavirus (COVID-19) patients not discontinuing angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) used to control hypertension. 

March 16, 2020 — The European Society of Cardiology (ESC) issued a statement March 13 recommending in novel coronavirus (COVID-19, and now clinically referred to as SARS‐CoV‐2) patients not discontinuing angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) used to control hypertension

Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak.

According to case fatality rates reported by the American College of Cardiology (ACC) in COVID-19 patients, comorbid patients have materially higher than the average population. The ACC said hypertension elevates patient mortality risk to 6 percent. Read more on ACC COVID-19 recommendations for the cardiovascular care team.

The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.

Based on initial reports on COVID-19 patients in China and subsequent evidence since the outbreak, arterial hypertension may be associated with increased risk of mortality in hospitalized COVID-19 infected subjects. There was a hypothesis  suggesting this might be a potential adverse effect of ACE-i or ARBs. 

"It has been suggested, especially on social media sites, that these commonly used drugs may increase both the risk of infection and the severity of SARS-CoV2," explained Prof. Giovanni de Simone, chair of the ESC Council on Hypertension, who wrote the statement. "The concern arises from the observation that, similar to the coronavirus causing SARS, the COVID-19 virus binds to a specific enzyme called ACE2 to infect cells, and ACE2 levels are increased following treatment with ACE-i and ARBs." 

ESC said in the statement that because of the social media-related amplification, patients taking these drugs for their high blood pressure and their doctors have become increasingly concerned, and, in some cases, have stopped taking their ACE-I or ARB medications.

"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it. Indeed, there is evidence from studies in animals suggesting that these medications might be rather protective against serious lung complications in patients with COVID-19 infection, but to date there is no data in humans," he said.

"There has been a lot of talk about the molecular and pathophysiology basis of the virus being mediated by the ACE-II receptors," said Thomas Maddox, M.D., MSc, FACC, the chairman of the American College of Cardiology (ACC) Science and Quality Committee, which recently created the ACC document on novel coronavirus (COVID-19) clinical guidance for the cardiovascular care team. "They are primarily in the lung, and that is why many people obviously have the pulmonary symptoms that are showing, but we know they are in the heart and intestine as well. We have started hearing reports of patients both domestically [in the U.S.] and overseas where they started to show signs of recovery from the lung disease and then all of a sudden appear to develop myocarditis or cardiomyopathy, and in some cases it is fatal."

He explained there was thinking that in the the expression of ACE-IIs, ACE-I inhibitors or ARBs might be able to inhibited the viral transport into the cells. However, the mechanisms behind the interactions of ACE-II and the ACI-Is and ARBs is very complex and there is no clear evidence that these drugs help inhibit, or aid the disease.

Read the related article COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues.

This includes some background information on the ACE receptors — VIDEO: The Latest Data on COVID-19 and Cardiovascular Disease

Watch the VIDEO: What Cardiologists Need to Know about COVID-19 — Interview with Thomas Maddox, M.D., which discusses this subject in more detail.

Watch the VIDEO: Cancelling Non-essential Cardiac Procedures During the COVID-19 Outbreak — an interview with SCCT President Ehtisham Mahmud, M.D.,

For more information: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang

 

Related Cardiology Related COVID-19 Content:

Statins May Reduce COVID-19 Severity

First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients

No Evidence Supporting Discontinuing RAAS Inhibitors in COVID-19 Patients

 

ACC COVID-19 recommendations for the cardiovascular care team

VIDEO: What Cardiologists Need to Know about COVID-19 — Interview with Thomas Maddox, M.D.

The Cardiac Implications of Novel Coronavirus

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

VIDEO: Imaging COVID-19 With Point-of-Care Ultrasound (POCUS)

 

CT Provides Best Diagnosis for Novel Coronavirus (COVID-19)

Radiology Lessons for Coronavirus From the SARS and MERS Epidemics

Deployment of Health IT in China’s Fight Against the COVID-19 Epidemic

Emerging Technologies Proving Value in Chinese Coronavirus Fight

Radiologists Describe Coronavirus CT Imaging Features

 

Coronavirus Update from the FDA

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Chest CT Findings of Patients Infected With Novel Coronavirus 2019-nCoV Pneumonia 

 

Additional COVID-19 Resources for Clinicians:

   ACC COVID-19 Hub page   

   Johns Hopkins Coronavirus Resource Center with inteavtive map of cases in U.S. and worldwide 

   World Health Organization (WHO) COVID-19 situation reports

   World Health Organization (WHO) coronavirus information page

   U.S. Food and Drug Administration (FDA) COVID-19 information page

   Centers for Disease Control (CDC) COVID-19 information page

   Centers for Medicare and Medicaid Services (CMS) frequently asked questions and answers (FAQs) for healthcare providers regarding COVID-19 related payments

Related Content

CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
Feature | Coronavirus (COVID-19) | April 13, 2021 | By Dave Fornell, Editor
April 13, 2021 — The U.S.
COVID-19 disrupted all aspects of science and medicine and unmasked striking disparities and opportunities for transformation. Coronavirus impact this past year is expected to result in a massive rise in new cases of chronic health conditions, including cardiolvascular disease and heart failure.
News | Coronavirus (COVID-19) | April 07, 2021
April 6, 2021 — A tsunami of chronic health conditions as a result of the...
MRI scan of a damaged heart. Blue means reduced blood flow, orange is good blood flow. In this figure the inferior part of the heart shows dark blue, so the myocardial blood flow is very reduced. The angiogram shows the coronary artery which supplies the blood to this part of the heart is occluded. The three colored MRI images show different slices of the heart — the basal mid and apical slices. Image courtesy of European Heart Journal #COVID #COVID19

MRI scan of a damaged heart. Blue means reduced blood flow, orange is good blood flow. In this figure the inferior part of the heart shows dark blue, so the myocardial blood flow is very reduced. The angiogram shows the coronary artery which supplies the blood to this part of the heart is occluded. The three colored MRI images show different slices of the heart — the basal mid and apical slices. Image courtesy of European Heart Journal

News | Coronavirus (COVID-19) | March 17, 2021
March 17, 2021 — Around 50% of patients who have been hospitalized with severe...
A study from Washington University School of Medicine in St. Louis provides evidence that the coronavirus can invade and replicate inside heart muscle cells, causing cell death and interfering with heart muscle contraction. The image of engineered heart tissue shows human heart muscle cells (red) infected with COVID-19 (SARS-CoV-2) (green). Image by Lina Greenberg.

A study from Washington University School of Medicine in St. Louis provides evidence that the coronavirus can invade and replicate inside heart muscle cells, causing cell death and interfering with heart muscle contraction. The image of engineered heart tissue shows human heart muscle cells (red) infected with COVID-19 (SARS-CoV-2) (green). Image by Lina Greenberg.

Feature | Coronavirus (COVID-19) | March 12, 2021
March 12, 2021 — Since early in the pandemic,...
Interactions between capillary function, inflammation, hypoxia, and neurotransmission. The expression of ACE2 and other SARS‐CoV‐2 entry factors on parenchymal cells and observations of infected cells in biopsy material hold important clues to understand COVID‐19‐related organ damage. COVID-19 Blood Vessel Damage May Cause Brain Fog and Other Long-hauler Symptoms

Interactions between capillary function, inflammation, hypoxia, and neurotransmission. The expression of ACE2 and other SARS‐CoV‐2 entry factors on parenchymal cells and observations of infected cells in biopsy material hold important clues to understand COVID‐19‐related organ damage. Find more figures and read the full study.

News | Coronavirus (COVID-19) | March 12, 2021
March 12, 2021 — A new review suggests that blood vessel damage and impaired oxygen delivery related to...
FDA Clears Third COVID-19 Vaccine From Janssen, Johnson and Johnson, J&J
News | Coronavirus (COVID-19) | March 01, 2021
March 1, 2021 — The U.S.
UK hospU.K. hospital admissions for heart attacks and heart failure were reduced by more than 50 percent in the spring of 2020 and by more than a third in the second wave of COVID-19 as people fear going to hospitals and ignore serious symptoms.ital admissions for heart attacks and heart failure have been reduced by COVID-19 as people fear going to hospitals. Getty Images #COVIDUK #COVID19

U.K. hospital admissions for heart attacks and heart failure were reduced by more than 50 percent in the spring of 2020 and by more than a third in the second wave of COVID-19 as people fear going to hospitals and ignore serious symptoms. Getty Images

News | Coronavirus (COVID-19) | February 24, 2021
February 24, 2021 — A study of admissions for acute myocardial infarction (AMI) and...
Vaccinating patients against the flu can go a long way to helping cardiology patients stay healthy and out of the hospital during the COVID-19 pandemic, freeing up beds for COVID patients. Left photo, Getty Images, right image of COVID-19 virus from the NIH.

Vaccinating patients against the flu can go a long way to helping cardiology patients stay healthy and out of the hospital during the COVID-19 pandemic, freeing up beds for COVID patients. Left photo, Getty Images, right image of COVID-19 virus from the NIH.

Feature | Coronavirus (COVID-19) | February 23, 2021 | By William Schaffner, M.D., and Allen J. Taylor, M.D.
While influenza (flu) is unpredictable, the 2020-2021 influenza season may present an unprecedented dual threat: co-c
The FDA says scientific evidence does not support COVID (coronavirus, SARS-CoV-2) transmission via food or packaging. Getty Images #COVID #COVID19 #SARSCoV2

The FDA says scientific evidence does not support COVID transmission via food or packaging. Getty Images

News | Coronavirus (COVID-19) | February 19, 2021
February 19, 2020 — After more than a year since the...